PTIX Relative Valuation
PTIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PTIX is overvalued; if below, it's undervalued.
Historical Valuation
Protagenic Therapeutics Inc (PTIX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.71. The fair price of Protagenic Therapeutics Inc (PTIX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.43
Fair
-0.10
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Protagenic Therapeutics Inc. (PTIX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-0.01
EV/EBIT
Protagenic Therapeutics Inc. (PTIX) has a current EV/EBIT of -0.01. The 5-year average EV/EBIT is -1.31. The thresholds are as follows: Strongly Undervalued below -6.98, Undervalued between -6.98 and -4.15, Fairly Valued between 1.52 and -4.15, Overvalued between 1.52 and 4.35, and Strongly Overvalued above 4.35. The current Forward EV/EBIT of -0.01 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Protagenic Therapeutics Inc. (PTIX) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Protagenic Therapeutics Inc. (PTIX) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
-0.05
P/FCF
Protagenic Therapeutics Inc. (PTIX) has a current P/FCF of -0.05. The 5-year average P/FCF is -1.60. The thresholds are as follows: Strongly Undervalued below -6.03, Undervalued between -6.03 and -3.82, Fairly Valued between 0.61 and -3.82, Overvalued between 0.61 and 2.83, and Strongly Overvalued above 2.83. The current Forward P/FCF of -0.05 falls within the Historic Trend Line -Fairly Valued range.
Protagenic Therapeutics Inc (PTIX) has a current Price-to-Book (P/B) ratio of 0.00. Compared to its 3-year average P/B ratio of 0.13 , the current P/B ratio is approximately -100.00% higher. Relative to its 5-year average P/B ratio of -0.76, the current P/B ratio is about -100.00% higher. Protagenic Therapeutics Inc (PTIX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -103.13%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -64.02% , the current FCF yield is about -100.00% lower.
0.00
P/B
Median3y
0.13
Median5y
-0.76
0.00
FCF Yield
Median3y
-103.13
Median5y
-64.02
Competitors Valuation Multiple
The average P/S ratio for PTIX's competitors is 0.00, providing a benchmark for relative valuation. Protagenic Therapeutics Inc Corp (PTIX) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PTIX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PTIX in the past 1 year is driven by Unknown.
People Also Watch
ICON
Icon Energy Corp
0.5401USD
-18.91%
KTTA
Pasithea Therapeutics Corp
0.938USD
-13.15%
CNET
ZW Data Action Technologies Inc
1.33USD
-3.62%
AZTR
Azitra Inc
0.3041USD
7.03%
SHPH
Shuttle Pharmaceuticals Holdings Inc
2.01USD
2.03%
YCBD
cbdMD Inc
1.1USD
-4.35%
TC
Token Cat Ltd
7.8299USD
0.00%
AQB
AquaBounty Technologies Inc
0.8857USD
0.00%
Frequently Asked Questions
Is Protagenic Therapeutics Inc (PTIX) currently overvalued or undervalued?
Protagenic Therapeutics Inc (PTIX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.71. The fair price of Protagenic Therapeutics Inc (PTIX) is between to according to relative valuation methord.
What is Protagenic Therapeutics Inc (PTIX) fair value?
PTIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Protagenic Therapeutics Inc (PTIX) is between to according to relative valuation methord.
How does PTIX's valuation metrics compare to the industry average?
The average P/S ratio for PTIX's competitors is 0.00, providing a benchmark for relative valuation. Protagenic Therapeutics Inc Corp (PTIX) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Protagenic Therapeutics Inc (PTIX) as of Jan 07 2026?
As of Jan 07 2026, Protagenic Therapeutics Inc (PTIX) has a P/B ratio of 0.00. This indicates that the market values PTIX at 0.00 times its book value.
What is the current FCF Yield for Protagenic Therapeutics Inc (PTIX) as of Jan 07 2026?
As of Jan 07 2026, Protagenic Therapeutics Inc (PTIX) has a FCF Yield of 0.00%. This means that for every dollar of Protagenic Therapeutics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for Protagenic Therapeutics Inc (PTIX) as of Jan 07 2026?
As of Jan 07 2026, Protagenic Therapeutics Inc (PTIX) has a Forward P/E ratio of -0.10. This means the market is willing to pay $-0.10 for every dollar of Protagenic Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Protagenic Therapeutics Inc (PTIX) as of Jan 07 2026?
As of Jan 07 2026, Protagenic Therapeutics Inc (PTIX) has a Forward P/S ratio of 0.00. This means the market is valuing PTIX at $0.00 for every dollar of expected revenue over the next 12 months.